Antengene Corporation LimitedHKEX: 6996

2026 Interim report

· Issued by Antengene Corporation Limited via HKEXnews

Filed with HKEX · Stock code 6996 · · 67 pages · English

Summary by 6ix AI

The report highlights a significant increase in revenue compared to the same period last year, primarily driven by licensing and collaboration agreements. Additionally, the company reported a turnaround from a loss to a profit during this reporting period, reflecting improved operational efficiency and increased drug development expenses. The report also outlines advancements in Antengene's product pipeline and collaborations with other biopharmaceutical companies.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Antengene Corporation Limited on 6ix

Earlier from Antengene

Later from Antengene

All Antengene news releases